➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Johnson and Johnson
Merck
Harvard Business School
McKinsey

Last Updated: August 1, 2021

DrugPatentWatch Database Preview

Patent: 10,101,343

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,101,343
Title:Anti-folate receptor alpha antibodies and uses thereof
Abstract: Described herein are antibodies, and antigen-binding fragments thereof, that are specific for folate receptor alpha, related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing cancers, such as breast cancer, thyroid cancer, colorectal cancer, endometrial cancer, fallopian tube cancer, ovarian cancer, or lung cancer, using the described antibodies, and antigen-binding fragments thereof. The methods involve determining the amount of folate receptor alpha in a sample derived from a subject and comparing this level with the level of folate receptor alpha in a control sample or reference sample.
Inventor(s): O\'Shannessy; Daniel John (Schwenksville, PA)
Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:15/434,326
Patent Claims:see list of patent claims

Details for Patent 10,101,343

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ⤷  Try it Free Eisai R&D Management Co., Ltd. (Tokyo, JP) 2031-07-15 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,101,343

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2012061759 ⤷  Try it Free
World Intellectual Property Organization (WIPO) 2013012722 ⤷  Try it Free
United States of America 2012207771 ⤷  Try it Free
United States of America 2013017195 ⤷  Try it Free
United States of America 2013183299 ⤷  Try it Free
United States of America 2014341897 ⤷  Try it Free
United States of America 2017168078 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
McKesson
Johnson and Johnson
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.